Published in Physician Law Weekly, February 22nd, 2006
"This is a transformational event for Cephalon," said Frank Baldino, Jr., chairman and CEO. "Continued PROVIGIL sales provide a new foundation for further accelerating Cephalon's growth over the next several years."
In connection with the settlements, Cephalon will grant Barr a nonexclusive royalty-bearing right to market and sell a generic version of PROVIGIL in the United States....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.